source
- BeOne culls five cancer programs and an autoimmune Phase 2BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…Endpoints · 2mo ago↗ source
- Lonza looks to ride ADC wave with upcoming factory, workforce expansionBASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount. T…Endpoints · 2mo ago↗ source
- FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLCAn sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLConclive · 2mo ago